Print Page    E-mail Page    RSS    E-mail Alerts 

Investors

Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.

We ar... more >

Stock Quotemore >
$2.32
 Stock is Down 0.03 (1.28%)
Bellerophon (Nasdaq: BLPH)
Data as of 04/24/18 11:40 a.m. ET
Minimum 20 minute delay
Recent Newsmore >
04/03/18
Bellerophon Therapeutics to Provide Corporate Update at H.C. Wainwright Annual Global Life Sciences Conference
WARREN, N.J., April 03, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will provide a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference, taking place April 8-10, 2018, in Monte Carlo, Monaco. Bellerophon Presentation Details Date:               Tuesday, April 10, 2018 Time:           ... 
03/15/18
Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
WARREN, N.J., March 15, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the fourth quarter and full-year ended December 31, 2017. “I am pleased to report continued progress in our clinical development programs evaluating INOpulse® to treat pulmonary hypertension in a wide range of unmet chronic diseases,” said Fabian Tenenbaum, C... 
01/29/18
Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension
WARREN, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that enrollment in its Phase 3 INOvation-1 study evaluating INOpulse® in patients with pulmonary arterial hypertension (PAH) now exceeds 100 patients, representing more than half of the anticipated enrollment.  As previously agreed with the U.S. Food and Drug Administration (FDA), an interim analysis of this trial will be performed by the Data ... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources